Abstract
To the Editor: The noninferiority trials of high-dose and low-dose calcium supplementation that were reported by Dwarkanath et al. (Jan. 11 issue)1 were premised on the assumption that high-dose calcium supplementation would reduce the risk of preeclampsia by more than half. This assumption was based on the mean effect from a Cochrane Database random-effects meta-analysis of 13 trials (involving 15,730 women), which was used to support a World Health Organization (WHO) recommendation.2,3 However, the trials that were included in the meta-analysis showed a high degree of heterogeneity, and the three largest trials, which accounted for 88% of the participants, showed .
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
